Health & Medicine - Investor's Business Daily (subscription)
March 30, 2007| Health & Medicine Investor's Business Daily (subscription) - Abbott plans to seek FDA permission to market Humira for psoriasis and juvenile rheumatoid arthritis by the summer. Analysts expect it to win these ... |
Nitec Pharma AG closes$ 26 million dollars Series B - American Venture Magazine (press release)
March 30, 2007| Nitec Pharma AG closes$ 26 million dollars Series B American Venture Magazine (press release), CA - The proceeds will be used to develop further Nitec’s lead product Lodotra™ in Rheumatoid Arthritis (RA) and other indications and to develop a second ... |
Juvenile Systemic Sclerosis: Still a Serious Disease - AAP Grand Rounds (subscription)
March 30, 2007| Juvenile Systemic Sclerosis: Still a Serious Disease AAP Grand Rounds (subscription), IL - A family history of autoimmune disease was present in 11.1%, most commonly rheumatoid arthritis. Children were less likely than adults to have organ ... |
REMICADE(R) Receives Approval in European Union for Dosing ... - Drug Newswire (press release)
March 30, 2007| REMICADE(R) Receives Approval in European Union for Dosing ... Drug Newswire (press release), CT - REMICADE treatment is to be initiated and supervised by qualified physicians experienced in the diagnosis and treatment of rheumatoid arthritis, ... |
Nitec Pharma AG Closes CHF 32 Million (approx. US$ 26 million ... - Drug Newswire (press release)
March 30, 2007| Nitec Pharma AG Closes CHF 32 Million (approx. US$ 26 million ... Drug Newswire (press release), CT - The proceeds will be used to develop further Nitec's lead product Lodotra(TM) in Rheumatoid Arthritis (RA) and other indications and to develop a second ... |
4SC AG Reports on Successful Financial Year 2006 - Drug Newswire (press release)
March 30, 2007| 4SC AG Reports on Successful Financial Year 2006 Drug Newswire (press release), CT - For the most advanced of the six pipeline projects with the drug candidate SC12267 for the treatment of rheumatoid arthritis, a clinical phase IIa study ... |